Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2022 Sep 23

PMID 36145514

Authors

Zvonimir Petric

Joao Goncalves

Paulo Paixao

Affiliations

Soon will be listed here.

Abstract

Monoclonal antibodies (MAbs) have revolutionized the treatment of many chronic inflammatory diseases, including inflammatory bowel disease (IBD). IBD is a term that comprises two quite similar, yet distinctive, disorders-Crohn's disease (CD) and ulcerative colitis (UC). Two blockbuster MAbs, infliximab (IFX) and adalimumab (ADL), transformed the pharmacological approach of treating CD and UC. However, due to the complex interplay of pharmacology and immunology, MAbs face challenges related to their immunogenicity, effectiveness, and safety. To ease the burden of IBD and other severe diseases, biosimilars have emerged as a cost-effective alternative to an originator product. According to the current knowledge, biosimilars of IFX and ADL in IBD patients are shown to be as safe and effective as their originators. The future of biosimilars, in general, is promising due to the potential of making the health care system more sustainable. However, their use is accompanied by misconceptions regarding their effectiveness and safety, as well as by controversy regarding their interchangeability. Hence, until a scientific consensus is achieved, scientific data on the long-term effectiveness and safety of biosimilars are needed.

Citing Articles

Assessment of IL-6 Pathway Inhibition in Gastrointestinal Behçet's Disease from Immunological and Clinical Perspectives.

Naganuma M, Takeno M, Celik A, Moots R, Pinton P, Hisamatsu T Biomedicines. 2025; 13(1).

PMID: 39857830 PMC: 11761229. DOI: 10.3390/biomedicines13010247.

Intestinal tissue levels of anti-TNF alpha, antibodies, and cytokines in paediatric Crohn disease.

Dotlacil V, Coufal S, Lerchova T, Zarubova K, Kucerova B, Tlaskalova-Hogenova H Sci Rep. 2025; 15(1):1138.

PMID: 39775097 PMC: 11707019. DOI: 10.1038/s41598-024-83858-7.

Infliximab in Inflammatory Bowel Disease: Leveraging Physiologically Based Pharmacokinetic Modeling in the Clinical Context.

Petric Z, Goncalves J, Paixao P Biomedicines. 2024; 12(9).

PMID: 39335488 PMC: 11429320. DOI: 10.3390/biomedicines12091974.

Clinical Pharmacology of Vinpocetine: Properties Revisited and Introduction of a Population Pharmacokinetic Model for Its Metabolite, Apovincaminic Acid (AVA).

Petric Z, Paixao P, Filipe A, Guimaraes Morais J Pharmaceutics. 2023; 15(10).

PMID: 37896263 PMC: 10610279. DOI: 10.3390/pharmaceutics15102502.

TNFα is a key trigger of inflammation in diet-induced non-obese MASLD in mice.

Burger K, Jung F, Baumann A, Brandt A, Staltner R, Sanchez V Redox Biol. 2023; 66:102870.

PMID: 37683301 PMC: 10493600. DOI: 10.1016/j.redox.2023.102870.

References

Vena G, Cassano N . Drug focus: adalimumab in the treatment of moderate to severe psoriasis. Biologics. 2009; 1(2):93-103. PMC: 2721299. View

Vulto A, Jaquez O . The process defines the product: what really matters in biosimilar design and production?. Rheumatology (Oxford). 2017; 56(suppl_4):iv14-iv29. PMC: 5850795. DOI: 10.1093/rheumatology/kex278. View

Lukas M, Malickova K, Kolar M, Bortlik M, Vasatko M, Machkova N . Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre. J Crohns Colitis. 2020; 14(7):915-919. DOI: 10.1093/ecco-jcc/jjaa001. View

Gamez-Belmonte R, Hernandez-Chirlaque C, Arredondo-Amador M, Aranda C, Gonzalez R, Martinez-Augustin O . Biosimilars: Concepts and controversies. Pharmacol Res. 2018; 133:251-264. DOI: 10.1016/j.phrs.2018.01.024. View

Bau M, Zacharias P, Ribeiro D, Boaron L, Steckert Filho A, Kotze P . SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN'S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB. Arq Gastroenterol. 2017; 54(4):328-332. DOI: 10.1590/S0004-2803.201700000-43. View

Chang H, Shakhnovich V, Frymoyer A, Funk R, Becker M, Park K . A population physiologically-based pharmacokinetic model to characterize antibody disposition in pediatrics and evaluation of the model using infliximab. Br J Clin Pharmacol. 2021; 88(1):290-302. PMC: 8714867. DOI: 10.1111/bcp.14963. View

Lee Y, Park Y, Park S, Kim T, Kim W, Cheon J . Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis. Gut Liver. 2020; 15(2):232-242. PMC: 7960969. DOI: 10.5009/gnl19433. View

Jones H, Rowland-Yeo K . Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst Pharmacol. 2013; 2:e63. PMC: 3828005. DOI: 10.1038/psp.2013.41. View

Klotz U, Teml A, Schwab M . Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007; 46(8):645-60. DOI: 10.2165/00003088-200746080-00002. View

10.

Fine S, Papamichael K, Cheifetz A . Etiology and Management of Lack or Loss of Response to Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2020; 15(12):656-665. PMC: 6935028. View

11.

Goulet D, Atkins W . Considerations for the Design of Antibody-Based Therapeutics. J Pharm Sci. 2019; 109(1):74-103. PMC: 6891151. DOI: 10.1016/j.xphs.2019.05.031. View

12.

Wright A, Sato Y, Okada T, Chang K, Endo T, Morrison S . In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure. Glycobiology. 2001; 10(12):1347-55. DOI: 10.1093/glycob/10.12.1347. View

13.

Allen P, Bonovas S, Danese S, Peyrin-Biroulet L . Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective. Expert Opin Biol Ther. 2019; 20(2):151-161. DOI: 10.1080/14712598.2020.1702020. View

14.

Silva F, Rodrigues B, Ayrizono M, Leal R . The Immunological Basis of Inflammatory Bowel Disease. Gastroenterol Res Pract. 2017; 2016:2097274. PMC: 5192315. DOI: 10.1155/2016/2097274. View

15.

Aronson J, Green A . Me-too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines lists. Br J Clin Pharmacol. 2020; 86(11):2114-2122. PMC: 7576625. DOI: 10.1111/bcp.14327. View

16.

Fernandes S, Bernardo S, Simoes C, Goncalves A, Valente A, Baldaia C . Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019; 26(2):263-270. DOI: 10.1093/ibd/izz131. View

17.

Colombel J, Sandborn W, Reinisch W, Mantzaris G, Kornbluth A, Rachmilewitz D . Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362(15):1383-95. DOI: 10.1056/NEJMoa0904492. View

18.

Dragoni G, Innocenti T, Galli A . Biomarkers of Inflammation in Inflammatory Bowel Disease: How Long before Abandoning Single-Marker Approaches?. Dig Dis. 2020; 39(3):190-203. DOI: 10.1159/000511641. View

19.

Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A . Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 2008; 58(5):1248-57. DOI: 10.1002/art.23447. View

20.

Sandborn W, Van Assche G, Reinisch W, Colombel J, DHaens G, Wolf D . Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2011; 142(2):257-65.e1-3. DOI: 10.1053/j.gastro.2011.10.032. View